All News

PD-L2 Biomarker May Predict Outcomes for Patients with ER-Positive Breast Cancer

February 8th 2023

The use of PD-L1 to predict outcomes highlights a possible opportunity to better understand which patients with ER-positive breast cancer may benefit from an immune checkpoint inhibitor.

Getting Back to Nature With Cancer

February 8th 2023

I don’t think of nature as a distraction to my cancer, masking the symptoms or the reality of my disease, but rather as a therapy that offers comfort and serenity with no negative side effects.

Tumor DNA May Predict Outcomes to Presurgical Treatment in Patients with Bladder Cancer

February 8th 2023

Data suggests an association between tumor DNA circulating in plasma and patient responses to neoadjuvant treatment.

Keytruda Approval Offers ‘Another Form of Insurance’ to Keep Lung Cancer From Returning

February 8th 2023

An expert discussed the recent approval of Keytruda for non-small cell lung cancer, and what patients with the disease need to know about the newly approved regimen.

Biomarker Algorithm May Predict Immunotherapy Outcomes Across Cancer Types

February 7th 2023

A new tool may identify more patients with cancer who can benefit from immunotherapy.

We Are All Unique in Our Experiences With Cancer

February 7th 2023

As a health care provider who specializes in lymphedema, I had a unique perspective when I was diagnosed with cancer.

Cancer-Related Muscle Aches May Not Be Fatal, But Are Quite Bothersome

February 7th 2023

Muscle aches related to cancer treatment were having a major impact on my life.

Physical Function May Decline in Women After Cancer Diagnosis, Throughout Survivorship

February 7th 2023

Postmenopausal women cancer survivors, including lung, breast, colorectal and endometrial cancer, may have a greater physical function decline than is generally expected at their age, which may lead to lower quality of life after treatment.

What Patients and Their Families Should Know About Hereditary Breast Cancer

February 7th 2023

As a part of its “Speaking Out” video series, CURE® spoke with genetic counselor, Angela Trepanier, on behalf of FORCE, to grasp a better understanding of what genetic breast cancer is and what it means for patients and their families.

Support is ‘Critical’ for Those Affected By Hereditary Cancers

February 7th 2023

As a part of its “Speaking Out” video series, on behalf of FORCE, CURE® spoke with Diane Rose, their vice president of volunteer programs about the importance of support for those affected by hereditary cancers.

Making Strides and Breaking Down Barriers in Genetic Testing for Breast Cancer

February 7th 2023

As a part of its “Speaking Out” video series, CURE® spoke with genetic counselor, Angela Trepanier, on behalf of FORCE, about disparities seen in genetic testing for caner.

The Value of Partnerships for Hereditary Cancers

February 7th 2023

As a part of its “Speaking Out” video series, on behalf of FORCE, CURE® spoke with Diane Rose, their vice president of volunteer programs, about how advocacy partnerships can bring greater awareness and education to patients with cancer and their families.

Clinical Trials in Hereditary Cancer Maybe A Key to Better Health Outcomes

February 7th 2023

As a part of its “Speaking Out” video series, on behalf of FORCE, CURE® spoke with Diane Rose, their vice president of volunteer programs, about clinical trials for patients with hereditary cancers and those who have a risk of developing.

Drug Offers Long-Term Heart Protection for Childhood Cancer Survivors

February 6th 2023

When children with cancer received dexrazoxane alongside their chemotherapy, they tended to have fewer heart complications in the short and long term.

Breast Cancer Treatment Recommendations May Differ From Ages 69 to 70

February 6th 2023

Guidelines often use a cutoff of 70 years old for breast cancer treatment, but patients should discuss goals of care with their team to further personalize their care.

The Sci-Fi World of Cancer Treatment

February 6th 2023

When I started cancer treatment, I had been cast in some sci-fi flick without prior consent.

FDA OKs Study of Novel CAR-T Cell Therapy for Myeloma

February 6th 2023

The Food and Drug Administration granted an investigational new drug application and green lit the continued study of GC012F for the treatment of patients with relapsed/refractory myeloma.

Eight Years and Counting Up: A Reflection on Life and Lessons of Cancer

February 6th 2023

The new year brings reflection on living fully with cancer.

The Value of Staying Active During Multiple Myeloma

February 5th 2023

As a part of its Speaking Out Video series, CURE® spoke with Kenny Capps, from Throwing Bones for a Cure, about the importance of staying active during a multiple myeloma diagnosis.

The Weight of Mental Health During Multiple Myeloma

February 5th 2023

As a part of its Speaking Out Video series, CURE® spoke with Kenny Capps, from Throwing Bones for a Cure, about the impact multiple myeloma has on a patient’s mental health and what they can do to help themselves.

The Future of Multiple Myeloma Treatment is Bright and Promising

February 5th 2023

As a part of its Speaking Out Video series, CURE® spoke with Dr. Saad Usmani, on behalf of Throwing Bones for a Cure, about the future of multiple myeloma treatments.

What Does It Mean When Multiple Myeloma Becomes Relapsed/Refractory?

February 5th 2023

How Patients and Survivors Are Closing the Care Gap on World Cancer Day and Beyond

February 4th 2023

In honor of World Cancer Day, we asked our readers what they do to raise funds and awareness since being diagnosed.

The Difficult Decisions Are the Most Important Ones When Fighting Cancer

February 4th 2023

I recently reflected on the most difficult decision I faced during my experience with cancer.

Adding Keytruda to Standard Chemo Improves Outcomes in Advanced Endometrial Cancer

February 3rd 2023

Findings from the phase 3 NRG-GY018 trial found that the addition of Keytruda to standard chemotherapy improved progression-free survival in patients with stage 3 to 4 or recurrent endometrial cancer.

White House Provides Cancer Moonshot Updates, Mets Broadcaster Reveals Cancer Diagnosis and More

February 3rd 2023

From funding updates on the Cancer Moonshot to Howie Rose’s bladder cancer diagnosis and more, here’s what’s happening in the oncology space this week.

Cancer and the Butterfly Effect

February 3rd 2023

Reflecting on World Cancer Day got me thinking about butterflies, a symbol of hope, but, according to the “Butterfly Effect” theory, a small flap of their wings could have major impacts on the world, which is not very different from cancer.

FDA Approves Trodelvy for HER2-Negative, HR-Positive Metastatic Breast Cancer

February 3rd 2023

The Food and Drug Administration approved Trodelvy for patients with pretreated, unresectable HR-positive, HER2-negative metastatic breast cancer.

Momelotinib Continues to Demonstrate Symptom Benefit for Patients With Myelofibrosis

February 3rd 2023

If approved by the FDA later this year, momelotinib could fulfill an area of unmet need for patients with myelofibrosis, according to an expert.

Medicaid Expansion Associated With Improved Breast Cancer Outcomes

February 2nd 2023

Patients with breast cancer who lived in Southern states with Medicaid expansion were less likely to be diagnosed with metastatic disease and more likely to receive treatment.